

Alessandra Mangia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3640894/alessandra-mangia-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

15,089
citations

52
h-index

121
g-index

279
ext. papers

16,872
ext. citations

7.7
avg, IF

5.8
L-index

#	Paper	IF	Citations
218	Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy.. <i>BMC Infectious Diseases</i> , 2022 , 22, 3	4	1
217	Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose.. <i>Frontiers in Public Health</i> , 2022 , 10, 847384	6	1
216	Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 2019-2026	5.9	5
215	Associations between Allelic Variants of the Human IgH 3' Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2021 , 9,	5.3	1
214	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
213	Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy. <i>United European Gastroenterology Journal</i> , 2021 , 9, 1109	5.3	3
212	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2021 , 223, 2090-2098	7	1
211	Dual proteotoxic stress accelerates liver injury via activation of p62-Nrf2. <i>Journal of Pathology</i> , 2021 , 254, 80-91	9.4	1
210	Hepatitis C virus micro-elimination: Where do we stand?. <i>World Journal of Gastroenterology</i> , 2021 , 27, 1728-1737	5.6	1
209	Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 772-778	5.1	2
208	Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1924-1928	0.7	1
207	High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55-85. <i>Pathogens</i> , 2021 , 10,	4.5	1
206	Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. <i>Pathologica</i> , 2021 , 113, 170-184	1.9	5
205	Current Management of Patients with HCV Genotype 2 2021 , 83-95		
204	Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. <i>Advances in Therapy</i> , 2021 , 38, 1397-1403	4.1	0
203	Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers. <i>Vaccines</i> , 2021 , 9,	5.3	6
202	Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. <i>Clinica Chimica Acta</i> , 2021 , 522, 144-151	6.2	10

201	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
200	Noninvasive Diagnosis of NAFLD and NASH. <i>Cells</i> , 2020 , 9,	7.9	55
199	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020 , 40, 1841-1852	7.9	28
198	Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?. <i>World Journal of Clinical Cases</i> , 2020 , 8, 5831-5834	1.6	8
197	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020 , 21, 348-359	4.4	2
196	Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. <i>BMC Gastroenterology</i> , 2020 , 20, 251	3	5
195	Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1096-1097	6.1	
194	Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. <i>Gastroenterology</i> , 2019 , 157, 227-241.e7	13.3	52
193	SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. <i>PLoS ONE</i> , 2019 , 14, e0215783	3.7	14
192	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019 , 70, e2-e3	13.4	9
191	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	4
190	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Gastroenterology</i> , 2019 , 156, 1496-1507.e7	13.3	20
189	SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. <i>Cells</i> , 2019 , 8,	7.9	13
188	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β dependent mechanisms. <i>Scientific Reports</i> , 2019 , 9, 1439	4.9	6
187	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1969-1979	11.6	7
186	THU-144-Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis. <i>Journal of Hepatology</i> , 2019 , 70, e225	13.4	5
185	Progress in promising anti-fibrotic therapies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 1145-1152	4.2	5
184	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1636-1641	0.7	16

183	Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019 , 43, 190-200	2.4	3
182	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 920-929	3.4	2
181	TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)ide Analogues. <i>Gastroenterology</i> , 2018 , 154, 1764-1777.e7	13.3	87
180	Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. <i>Journal of Hepatology</i> , 2018 , 68, S67-S68	13.4	8
179	Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. <i>PLoS ONE</i> , 2018 , 13, e0200568	3.7	7
178	Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. <i>Antiviral Therapy</i> , 2018 , 23, 229-238	1.6	43
177	Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 344-353	3.4	3
176	Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. <i>Liver International</i> , 2018 , 38, 443-450	7.9	34
175	Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STILy observational study. <i>Medicine (United States)</i> , 2018 , 97, e11307	1.8	2
174	High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV). <i>Journal of Hepatology</i> , 2018 , 68, S273-S274	13.4	2
173	A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 564-573	6.1	8
172	Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus. <i>European Review for Medical and Pharmacological Sciences</i> , 2018 , 22, 7024-7033	2.0	1
171	NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. <i>Journal of Hepatology</i> , 2017 , 66, 910-918	13.4	165
170	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017 , 65, 1840-1850	11.2	51
169	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017 , 37, 514-528	7.9	71
168	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017 , 66, 1282-1299	13.4	58
167	IFN- β , not IFN- α , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017 , 49, 795-800	36.3	72
166	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017 , 16, 523-541	13.6	66

165	Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. <i>Journal of Hepatology</i> , 2017 , 66, 711-717	13.4	19
164	TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2017 , 153, 1448-1449	13.3	6
163	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017 , 30, 1253-1265	3	2
162	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. <i>Scientific Reports</i> , 2017 , 7, 15843	4.9	3
161	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. <i>Journal of Hepatology</i> , 2017 , 67, 680-686	13.4	29
160	Combined GS-4774 and tenofovir therapy can improve HBV-specific T cell responses in patients with chronic active hepatitis B. <i>Journal of Hepatology</i> , 2017 , 66, S29	13.4	6
159	Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 424-431	6.1	24
158	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 421-430.e6	6.9	62
157	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <i>Annals of Gastroenterology</i> , 2017 , 30, 327-343	2.2	5
156	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1479-1481	11.6	72
155	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016 , 15, 1145-1160	13.6	69
154	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1042-1048	11.6	45
153	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016 , 7, 12757	17.4	73
152	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2016 , 48, 860-8	3.3	14
151	Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection. <i>Journal of Biomedical Nanotechnology</i> , 2016 , 12, 770-80	4	17
150	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016 , 64, 34-46	11.2	65
149	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 739-50	5.1	12
148	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016 , 64, 390-398	13.4	55

147	genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. <i>SpringerPlus</i> , 2016 , 5, 1990		9
146	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. <i>PLoS ONE</i> , 2016 , 11, e0151703	3.7	5
145	Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. <i>Hepatology</i> , 2016 , 63, 1112-9	11.2	56
144	The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. <i>Liver International</i> , 2016 , 36, 971-6	7.9	28
143	Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans. <i>Hepatology</i> , 2016 , 64, 2264-2265	11.2	2
142	Sofosbuvir and Velpatasvir for Patients with HCV Infection. <i>New England Journal of Medicine</i> , 2016 , 374, 1687-8	59.2	11
141	Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1B Chimeras. <i>Journal of Hepatology</i> , 2016 , 64, S136	13.4	7
140	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015 , 62, 25-30	11.2	71
139	Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. <i>PLoS ONE</i> , 2015 , 10, e0117420	3.7	40
138	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , 2015 , 62, 79-86	11.2	207
137	Interferon- γ s12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015 , 6, 6422	17.4	127
136	Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. <i>Liver International</i> , 2015 , 35, 482-8	7.9	4
135	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 469-80	3.4	6
134	O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. <i>Journal of Hepatology</i> , 2015 , 62, S221	13.4	49
133	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015 , 10, e0138503	3.7	3
132	The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. <i>BioMed Research International</i> , 2015 , 2015, 731469	3	22
131	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015 , 373, 2599-607	59.2	758
130	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015 , 373, 2608-17	59.2	613

129	The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. <i>PLoS ONE</i> , 2015 , 10, e0134594	3.7	16
128	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. <i>Journal of Hepatology</i> , 2014 , 61, 235-41	13.4	33
127	Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2014 , 370, 1889-98	59.2	1402
126	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014 , 15, 500-5	4.4	43
125	75. <i>Cytokine</i> , 2014 , 70, 45-46	4	1
124	P1112 LONG TERM FOLLOW-UP OF PATIENTS TREATED WITH SOFOSBUVIR IN THE FISSION, POSITRON, FUSION AND NEUTRINO PHASE 3 STUDIES. <i>Journal of Hepatology</i> , 2014 , 60, S449	13.4	8
123	Reply to: "Built-in bias in HCV clearance in acute HCV infection". <i>Journal of Hepatology</i> , 2014 , 60, 461-3	13.4	
122	Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). <i>Digestive and Liver Disease</i> , 2014 , 46, 18-24	3.3	9
121	Sofosbuvir and ribavirin in HCV genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014 , 370, 1993-2001	39.2	671
120	Phyto-liposomes as nanoshuttles for water-insoluble silybin-phospholipid complex. <i>International Journal of Pharmaceutics</i> , 2014 , 471, 173-81	6.5	46
119	Clinical significance of the CCR5delta32 allele in hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e106424	3.7	7
118	Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. <i>BioMed Research International</i> , 2014 , 2014, 710642	3	10
117	Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. <i>Liver International</i> , 2014 , 34, e308-16	7.9	4
116	In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions. <i>Liver International</i> , 2014 , 34, e217-28	7.9	1
115	Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. <i>Digestive and Liver Disease</i> , 2014 , 46 Suppl 5, S179-85	3.3	24
114	Reduced IFN γ activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. <i>Nature Communications</i> , 2014 , 5, 5699	17.4	95
113	O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY. <i>Journal of Hepatology</i> , 2014 , 60, S523-S524	13.4	3
112	Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. <i>PLoS ONE</i> , 2014 , 9, e110284	3.7	5

111	Cytokine profile evaluation in patients with hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9261-9	5.6	18
110	Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHEYS Cohort. <i>Hepato-Gastroenterology</i> , 2014 , 61, 1094-106		2
109	Update on the treatment of patients with non-genotype 1 hepatitis C virus infection. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1294-300	11.6	5
108	Insulin resistance, steatosis and hepatitis C virus. <i>Hepatology International</i> , 2013 , 7 Suppl 2, 782-9	8.8	26
107	Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. <i>Journal of Hepatology</i> , 2013 , 59, 221-8	13.4	32
106	Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis. <i>Journal of Hepatology</i> , 2013 , 58, 1259	13.4	0
105	5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAIVE GT2/3 HCV-INFECTED PATIENTS (FISSION). <i>Journal of Hepatology</i> , 2013 , 58, S3	13.4	8
104	Futility of antiviral treatments for hepatitis C: an evolving concept entering the direct antiviral agents era. <i>Digestive and Liver Disease</i> , 2013 , 45, 356-61	3.3	6
103	Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. <i>Hepatology</i> , 2013 , 58, 65-72	11.2	130
102	Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013 , 57, 974-84	11.2	58
101	Sofosbuvir for previously untreated chronic hepatitis C infection. <i>New England Journal of Medicine</i> , 2013 , 368, 1878-87	59.2	1380
100	Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. <i>Annals of Internal Medicine</i> , 2013 , 158, 235-45	8	159
99	Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6. <i>American Journal of Gastroenterology</i> , 2013 , 108, S123	0.7	2
98	Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8924-8	5.6	17
97	Treatment of non-genotype 1 hepatitis C virus patients. <i>Current Gastroenterology Reports</i> , 2012 , 14, 87-93		7
96	High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHEYS cohort confirm results from randomized clinical trials. <i>Hepatology</i> , 2012 , 56, 2039-50	11.2	83
95	What's new in HCV genotype 2 treatment. <i>Liver International</i> , 2012 , 32 Suppl 1, 135-40	7.9	11
94	Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. <i>Journal of Viral Hepatitis</i> , 2012 , 19 Suppl 1, 52-9	3.4	14

93	Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 92-104	6.1	36
92	Boceprevir for untreated chronic HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2011 , 364, 1195-206	59.2	2074
91	Chronic viral hepatitis: the histology report. <i>Digestive and Liver Disease</i> , 2011 , 43 Suppl 4, S331-43	3.3	34
90	IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients. <i>Antiviral Therapy</i> , 2011 , 16, 1309-16	1.6	15
89	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1202-16	6.1	94
88	Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. <i>Liver International</i> , 2011 , 31, 36-41	7.9	9
87	Hepatitis C pharmacogenetics: state of the art in 2010. <i>Hepatology</i> , 2011 , 53, 336-45	11.2	120
86	Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. <i>Hepatology</i> , 2011 , 53, 389-95	11.2	60
85	Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. <i>Hepatology</i> , 2011 , 54, 772-80	11.2	54
84	Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. <i>Hepatology</i> , 2011 , 54, 789-800	11.2	51
83	High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient outcome. <i>International Journal of Cancer</i> , 2011 , 129, 536-45	7.5	37
82	1331 LACK OF ASSOCIATION BETWEEN IL28B VARIANTS AND HBSAG CLEARANCE AFTER INTERFERON TREATMENT. <i>Journal of Hepatology</i> , 2011 , 54, S525	13.4	6
81	Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1346-53	6.1	12
80	Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR- γ in Huh-7 cells. <i>Journal of General Virology</i> , 2010 , 91, 1678-86	4.9	54
79	Tailoring the length of antiviral treatment for hepatitis C. <i>Gut</i> , 2010 , 59, 1-5	19.2	25
78	1170 IL28B C/C POLYMORPHISM IS PREDICTIVE OF SPONTANEOUS HCV RNA CLEARANCE IN PATIENTS WITH THALASSEMIA MAJOR. <i>Journal of Hepatology</i> , 2010 , 52, S452	13.4	3
77	Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010 , 42, 81-91	3.3	52
76	Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. <i>Journal of Hepatology</i> , 2010 , 53, 1000-5	13.4	26

75	An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. <i>Gastroenterology</i> , 2010 , 139, 821-7, 827.e1	13.3	259
74	126 PREDICTIVE ROLE OF IL28B C/C GENOTYPE ON SVR AND RVR IN PATIENTS WITH GENOTYPE 2/3 CHRONIC INFECTION. <i>Journal of Hepatology</i> , 2010 , 52, S56-S57	13.4	2
73	Treating fatty liver for the prevention of cardiovascular diseases. <i>Hepatology</i> , 2010 , 52, 1174-5	11.2	4
72	Optimal dosage of ribavirin. <i>Hepatology</i> , 2010 , 52, 1174	11.2	
71	Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2009 , 49, 358-63	11.2	52
70	SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009 , 49, 1821-7	11.2	132
69	Management of patients with hepatitis C virus genotype 2 or 3: comments on updated American Association for the Study of Liver Diseases practice guidelines. <i>Hepatology</i> , 2009 , 50, 323; author reply 324-5	11.2	1
68	Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 28-35	3.4	5
67	Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins. <i>Liver International</i> , 2009 , 29, 661-9	7.9	23
66	630 RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B. <i>Journal of Hepatology</i> , 2009 , 50, S232	13.4	2
65	Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 397-404	6.1	92
64	The use of molecular assays in the management of viral hepatitis. <i>Digestive and Liver Disease</i> , 2008 , 40, 395-404	3.3	13
63	8 FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION. <i>Journal of Hepatology</i> , 2008 , 48, S6	13.4	2
62	756 LARGE-SCALE MULTICENTER COMPARISON OF THREE ALGORITHMS COMBINING SERUM NON-INVASIVE MARKERS FOR LIVER FIBROSIS IN CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2008 , 48, S282	13.4	3
61	Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. <i>Journal of Medical Economics</i> , 2008 , 11, 151-63	2.4	6
60	Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1966-72	0.7	15
59	Hepatitis C infection in patients with chronic kidney disease. <i>International Journal of Artificial Organs</i> , 2008 , 31, 15-33	1.9	10
58	Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. <i>Hepatology</i> , 2008 , 47, 43-50	11.2	196

57	Are HCV genotypes 2 and 3 the same or different?. <i>Current Hepatitis Reports</i> , 2008 , 7, 88-92		1
56	Short treatment to patients with genotype 2 or 3. <i>Hepatology</i> , 2008 , 48, 694	11.2	4
55	Reply:. <i>Hepatology</i> , 2008 , 48, 1020-1021	11.2	1
54	Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007 , 39, 397-408	3.3	172
53	Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. <i>Hepatology</i> , 2007 , 45, 579-87	11.2	517
52	The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. <i>Hepatology</i> , 2007 , 45, 1164-71	11.2	193
51	Short-duration therapy for hepatitis C: suitable for all?. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 221-7	3.4	7
50	Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV. <i>New England Journal of Medicine</i> , 2007 , 357, 1660; author reply 1661-2	59.2	1
49	Hepatitis C virus chronic infection and oral lichen planus: an Italian case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 647-52	2.2	23
48	[7] IN PTS WHO CLEAR HCVRNA AT WEEK 12, SVR IS HIGHER AFTER 72 THAN AFTER 48 WEEKS TX: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (RCT). <i>Journal of Hepatology</i> , 2007 , 46, S6	13.4	3
47	Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. <i>Gastroenterology</i> , 2006 , 130, 1636-42	13.3	449
46	Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. <i>Drugs</i> , 2006 , 66, 1807-15	2.1	22
45	Short-term treatment duration for HCV-2 and HCV-3 infected patients. <i>Digestive and Liver Disease</i> , 2006 , 38, 741-8	3.3	22
44	HLA and enteric antineuronal antibodies in patients with achalasia. <i>Neurogastroenterology and Motility</i> , 2006 , 18, 520-5	4	29
43	An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. <i>Journal of Hepatology</i> , 2005 , 42, 744-51	13.4	145
42	Unusual sonographic appearance of a haemorrhagic biliary cyst. <i>European Journal of Radiology Extra</i> , 2005 , 54, 103-105		
41	Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 745-51	2.2	67
40	A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2005 , 12, 292-9	3.4	41

39	Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 769-74	6.1	32
38	BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005 , 578, 395-405	3.3	44
37	Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection. <i>New England Journal of Medicine</i> , 2005 , 353, 1182-3; author reply 1182-3	59.2	4
36	Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. <i>New England Journal of Medicine</i> , 2005 , 352, 2609-17	59.2	534
35	External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. <i>American Journal of Gastroenterology</i> , 2005 , 100, 868-73	0.7	29
34	Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 331-7	6.1	9
33	Treatment of patients with HCV infection with or without liver biopsy. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 536-42	3.4	16
32	IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. <i>Cytokine</i> , 2004 , 25, 103-9	4	83
31	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. <i>Journal of Hepatology</i> , 2004 , 40, 478-83	13.4	35
30	93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study. <i>Journal of Hepatology</i> , 2004 , 40, 34	13.4	3
29	Use of experimental design for optimisation of the cold plasma ICP-MS determination of lithium, aluminum and iron in soft drinks and alcoholic beverages. <i>Rapid Communications in Mass Spectrometry</i> , 2003 , 17, 251-6	2.2	14
28	Clinical management of HCV carriers with normal aminotransferase levels. <i>Digestive and Liver Disease</i> , 2003 , 35, 362-9	3.3	41
27	HCV chronic infection and CCR5-delta32/delta32. <i>Gastroenterology</i> , 2003 , 124, 868-9; author reply 869-70	3.3	25
26	PEG-IFN alfa-2a (40kd) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naïve patients with chronic hepatitis C (CHC). <i>Journal of Hepatology</i> , 2003 , 38, 146	13.4	3
25	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002 , 51, 864-9	19.2	19
24	Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 3729-34	9.7	135
23	Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study. <i>Digestive and Liver Disease</i> , 2002 , 34, 285-9	3.3	13
22	High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. <i>Journal of Hepatology</i> , 2002 , 37, 109-16	13.4	19

21	A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. <i>Hepatology</i> , 2001 , 33, 989-93	11.2	38
20	To biopsy or not to biopsy. <i>Hepatology</i> , 2001 , 34, 438; author reply 439	11.2	6
19	Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. <i>Journal of Hepatology</i> , 2001 , 34, 441-6	13.4	25
18	Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2000 , 51, 1-7	5.2	175
17	Anticardiolipin antibodies in patients with liver disease. <i>American Journal of Gastroenterology</i> , 1999 , 94, 2983-7	0.7	68
16	Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 1999 , 59, 277-80	19.7	19
15	HLA class II favors clearance of HCV infection and progression of the chronic liver damage. <i>Journal of Hepatology</i> , 1999 , 30, 984-9	13.4	100
14	Novel approach to separation and identification of organometallic compounds in complex mixtures by means of particle beam liquid chromatography/mass spectrometry: the case of diphosphine-substituted selenido iron and ruthenium clusters 1998 , 12, 225-230		12
13	Development of a multigenic plasmid vector for HCV DNA immunization. <i>Research in Virology</i> , 1998 , 149, 315-9		5
12	HCV and diabetes mellitus: evidence for a negative association. <i>American Journal of Gastroenterology</i> , 1998 , 93, 2363-7	0.7	90
11	Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial. <i>Journal of Hepatology</i> , 1997 , 27, 56-62	13.4	41
10	HCV genotypes in patients with liver disease of different stages and severity. <i>Journal of Hepatology</i> , 1997 , 26, 1173-8	13.4	42
9	Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? [letter]. <i>Blood</i> , 1996 , 88, 752-754	2.2	39
8	Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 2447-52	4	37
7	Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. <i>Leukemia</i> , 1996 , 10, 1209-13	10.7	33
6	Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 1994 , 43, 125-8	19.7	24
5	Gallbladder emptying in patients with primary achalasia. <i>Digestion</i> , 1992 , 52, 152-6	3.6	7
4	Thromboxane production in diabetes mellitus. <i>Research in Clinic and Laboratory</i> , 1986 , 16, 539-42		2

- 3 Thrombosis, recurrent abortions and intrauterine foetal death in a patient with lupus anticoagulant. *Clinical Rheumatology*, **1985**, 4, 455-7 3.9 2
- 2 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3 97-103
- 1 Management of Patients with Genotype 3 Chronic Hepatitis C: Can we Change the Duration of Therapy? 88-93